MR-guided proton therapy: a review and a preview.
Image guidance
Magnetic resonance imaging
Proton therapy
Journal
Radiation oncology (London, England)
ISSN: 1748-717X
Titre abrégé: Radiat Oncol
Pays: England
ID NLM: 101265111
Informations de publication
Date de publication:
29 May 2020
29 May 2020
Historique:
received:
18
11
2019
accepted:
17
05
2020
entrez:
31
5
2020
pubmed:
31
5
2020
medline:
7
4
2021
Statut:
epublish
Résumé
The targeting accuracy of proton therapy (PT) for moving soft-tissue tumours is expected to greatly improve by real-time magnetic resonance imaging (MRI) guidance. The integration of MRI and PT at the treatment isocenter would offer the opportunity of combining the unparalleled soft-tissue contrast and real-time imaging capabilities of MRI with the most conformal dose distribution and best dose steering capability provided by modern PT. However, hybrid systems for MR-integrated PT (MRiPT) have not been realized so far due to a number of hitherto open technological challenges. In recent years, various research groups have started addressing these challenges and exploring the technical feasibility and clinical potential of MRiPT. The aim of this contribution is to review the different aspects of MRiPT, to report on the status quo and to identify important future research topics. Four aspects currently under study and their future directions are discussed: modelling and experimental investigations of electromagnetic interactions between the MRI and PT systems, integration of MRiPT workflows in clinical facilities, proton dose calculation algorithms in magnetic fields, and MRI-only based proton treatment planning approaches. Although MRiPT is still in its infancy, significant progress on all four aspects has been made, showing promising results that justify further efforts for research and development to be undertaken. First non-clinical research solutions have recently been realized and are being thoroughly characterized. The prospect that first prototype MRiPT systems for clinical use will likely exist within the next 5 to 10 years seems realistic, but requires significant work to be performed by collaborative efforts of research groups and industrial partners.
Sections du résumé
BACKGROUND
BACKGROUND
The targeting accuracy of proton therapy (PT) for moving soft-tissue tumours is expected to greatly improve by real-time magnetic resonance imaging (MRI) guidance. The integration of MRI and PT at the treatment isocenter would offer the opportunity of combining the unparalleled soft-tissue contrast and real-time imaging capabilities of MRI with the most conformal dose distribution and best dose steering capability provided by modern PT. However, hybrid systems for MR-integrated PT (MRiPT) have not been realized so far due to a number of hitherto open technological challenges. In recent years, various research groups have started addressing these challenges and exploring the technical feasibility and clinical potential of MRiPT. The aim of this contribution is to review the different aspects of MRiPT, to report on the status quo and to identify important future research topics.
METHODS
METHODS
Four aspects currently under study and their future directions are discussed: modelling and experimental investigations of electromagnetic interactions between the MRI and PT systems, integration of MRiPT workflows in clinical facilities, proton dose calculation algorithms in magnetic fields, and MRI-only based proton treatment planning approaches.
CONCLUSIONS
CONCLUSIONS
Although MRiPT is still in its infancy, significant progress on all four aspects has been made, showing promising results that justify further efforts for research and development to be undertaken. First non-clinical research solutions have recently been realized and are being thoroughly characterized. The prospect that first prototype MRiPT systems for clinical use will likely exist within the next 5 to 10 years seems realistic, but requires significant work to be performed by collaborative efforts of research groups and industrial partners.
Identifiants
pubmed: 32471500
doi: 10.1186/s13014-020-01571-x
pii: 10.1186/s13014-020-01571-x
pmc: PMC7260752
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
129Subventions
Organisme : National Health and Medical Research Council
ID : 1036078
Organisme : Cancer Council NSW
ID : APP1128336
Organisme : IBA
ID : N/A
Organisme : Austrian Science Fund
ID : P 30065-B27
Références
Acta Oncol. 2019 Oct;58(10):1429-1434
pubmed: 31271093
Int J Radiat Oncol Biol Phys. 2018 Jan 1;100(1):244-253
pubmed: 29079119
Phys Med Biol. 2018 Aug 10;63(16):165005
pubmed: 30020079
Int J Radiat Oncol Biol Phys. 2019 Nov 1;105(3):495-503
pubmed: 31271823
Med Phys. 2018 May;45(5):2195-2204
pubmed: 29532490
Med Phys. 2012 Nov;39(11):6818-37
pubmed: 23127075
Med Phys. 2018 Jul;45(7):3429-3434
pubmed: 29763970
Phys Med Biol. 2017 Feb 21;62(4):1358-1377
pubmed: 28114107
Phys Med Biol. 2008 Oct 21;53(20):5615-22
pubmed: 18799829
Phys Med Biol. 2019 Nov 04;64(21):215015
pubmed: 31509819
Radiother Oncol. 2020 Mar;144:79-85
pubmed: 31734604
Med Phys. 2018 May 28;:
pubmed: 29807390
Radiat Oncol. 2019 Jun 3;14(1):92
pubmed: 31167658
Phys Med Biol. 2012 Dec 7;57(23):7783-97
pubmed: 23128424
Acta Oncol. 2018 Nov;57(11):1521-1531
pubmed: 29842815
Phys Med. 2017 Dec;44:139-149
pubmed: 28242140
Med Phys. 2014 Nov;41(11):111713
pubmed: 25370627
Med Phys. 2018 Nov;45(11):e1086-e1095
pubmed: 30421805
Clin Oncol (R Coll Radiol). 2018 May;30(5):293-298
pubmed: 29551567
Phys Med Biol. 2018 Nov 22;63(23):23LT01
pubmed: 30465549
Phys Med Biol. 2019 Jul 16;64(14):145015
pubmed: 31146267
Phys Med Biol. 2015 Mar 21;60(6):2257-69
pubmed: 25715661
Phys Med Biol. 2019 Aug 01;64(15):15NT02
pubmed: 31158831
Phys Med Biol. 2017 Nov 21;62(24):9159-9176
pubmed: 29076458
Radiat Oncol. 2013 Mar 06;8:51
pubmed: 23497586
Phys Med Biol. 2018 Nov 20;63(22):22TR03
pubmed: 30457121
Phys Med Biol. 2017 Feb 21;62(4):1548-1564
pubmed: 28121631
Med Phys. 2020 Mar;47(3):1238-1248
pubmed: 31876300
Med Phys. 2020 Mar;47(3):909-916
pubmed: 31880819
Med Phys. 2013 Jun;40(6):061702
pubmed: 23718581
Phys Med Biol. 2014 Dec 7;59(23):7501-19
pubmed: 25393873
Med Phys. 2015 May;42(5):2113-24
pubmed: 25979006
Phys Med Biol. 2019 Feb 25;64(5):055010
pubmed: 30669135
Radiat Oncol. 2017 Jan 26;12(1):28
pubmed: 28126030
Phys Med Biol. 2012 Sep 7;57(17):N329-37
pubmed: 22892827
Phys Med Biol. 2008 Sep 7;53(17):4825-53
pubmed: 18701772
Med Phys. 2017 Mar;44(3):1149-1156
pubmed: 28090633
Med Phys. 2017 Aug;44(8):e77-e90
pubmed: 28547820
Med Phys. 2016 Aug;43(8):4634
pubmed: 27487880
Phys Med Biol. 2015 Aug 7;60(15):5955-69
pubmed: 26182957
Med Phys. 2018 Nov;45(11):5129-5137
pubmed: 30269345
Med Phys. 2016 Apr;43(4):1700
pubmed: 27036568
Int J Radiat Oncol Biol Phys. 2018 Jan 1;100(1):199-217
pubmed: 29254773
Med Phys. 2017 Jun;44(6):2332-2344
pubmed: 28295434
Phys Med Biol. 2017 Aug 21;62(18):7233-7248
pubmed: 28749375
Phys Med Biol. 2012 Jun 7;57(11):R99-117
pubmed: 22571913
Phys Med Biol. 2019 Mar 18;64(6):065021
pubmed: 30641496
Radiother Oncol. 2013 Dec;109(3):414-8
pubmed: 24268939
Med Phys. 2014 Jan;41(1):011704
pubmed: 24387496
Phys Med Biol. 2016 Oct 03;61(20):7347-7362
pubmed: 27694712
Phys Med Biol. 2017 Oct 19;62(21):8470-8482
pubmed: 29047455
Med Phys. 2015 Jun;42(6):2967-78
pubmed: 26127050